Sue Rataj - Bayer Aktiengesellscha Member of the Supervisory Board
| BAYZF Stock | USD 29.28 0.20 0.69% |
Executive
Ms. Sue H. Rataj was Member of the Supervisory Board at Bayer Aktiengesellschaft since April 27, 2012. She is Member of the Board of Directors at Cabot Corporationrationration. She is Member of the Board of Directors of Cabot Corporation and Member of the Board of Directors of Agilent Technologies Inc. In 1985 she obtained BS degree in Economics Finance from the University of Illinois and in 1988 an MBA degree in Finance from the Northwestern University, Kellogg Graduate School. since 2012.
| Age | 59 |
| Tenure | 12 years |
| Professional Marks | MBA |
| Phone | 49 214 30 1 |
| Web | https://www.bayer.com |
Bayer Aktiengesellscha Management Efficiency
The company has return on total asset (ROA) of 0.0576 % which means that it generated a profit of $0.0576 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.13 %, meaning that it generated $0.13 on every $100 dollars invested by stockholders. Bayer Aktiengesellscha's management efficiency ratios could be used to measure how well Bayer Aktiengesellscha manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Dalton III | Merck Company | 57 | |
| Thomas Larsen | AstraZeneca PLC ADR | N/A | |
| Paul Arkel | Novartis AG ADR | N/A | |
| Eric Dozier | Eli Lilly and | 56 | |
| Michele Galen | Novartis AG ADR | N/A | |
| Samir Shah | Novartis AG ADR | N/A | |
| Peter Dannenbaum | Merck Company | N/A | |
| Sophie KornowskiBonnet | Roche Holding Ltd | 54 | |
| Jessica Moore | Johnson Johnson | N/A | |
| Jim Greffet | Eli Lilly and | N/A | |
| Chirfi Guindo | Merck Company | 58 | |
| Donald Zakrowski | Eli Lilly and | N/A | |
| Steffen Lang | Novartis AG ADR | 57 | |
| Bertrand Bodson | Novartis AG ADR | 44 | |
| Erwin Vanhaecke | Novartis AG ADR | N/A | |
| Guy MD | Johnson Johnson | N/A | |
| Winselow Tucker | Eli Lilly and | 56 | |
| Vasant MD | Novartis AG ADR | 48 | |
| John Tsai | Novartis AG ADR | 54 | |
| Andrew Barnett | AstraZeneca PLC ADR | N/A | |
| Urs Jaisli | Roche Holding Ltd | 62 | |
Management Performance
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0576 |
Bayer Aktiengesellschaft Leadership Team
Elected by the shareholders, the Bayer Aktiengesellscha's board of directors comprises two types of representatives: Bayer Aktiengesellscha inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bayer. The board's role is to monitor Bayer Aktiengesellscha's management team and ensure that shareholders' interests are well served. Bayer Aktiengesellscha's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bayer Aktiengesellscha's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Oliver Maier, Head Relations | ||
| Heiko Schipper, Member of the Management Board, Head of the Consumer Health Division | ||
| Thomas Fischer, Member of the Supervisory Board | ||
| Marijn Dekkers, Chairman of Management Board and CEO | ||
| Helmut Panke, Member of the Supervisory Board | ||
| Reiner Hoffmann, Member of the Supervisory Board | ||
| Sue Rataj, Member of the Supervisory Board | ||
| Petra ReinboldKnape, Member of the Supervisory Board | ||
| Dieter Weinand, Member of the Management Board and Head of the Pharmaceuticals Division, North America Region | ||
| Werner Baumann, Chief Strategy and Portfolio Officer and Member of Management Board | ||
| Sarena Lin, Labor Officer | ||
| Simone BagelTrah, Member of the Supervisory Board | ||
| Michael SchmidtKiessling, Member of the Supervisory Board | ||
| ErnstLudwig Winnacker, Member of the Supervisory Board | ||
| Colleen Goggins, Member of the Supervisory Board | ||
| Heinz Webers, Member of the Supervisory Board | ||
| Johanna Faber, Member of the Supervisory Board | ||
| Frank Loellgen, Member of the Supervisory Board | ||
| Andre Broich, Member of the Supervisory Board | ||
| Liam Condon, Member of Management Board and CEO of Bayer Cropscience | ||
| Rodrigo Santos, Member Division | ||
| Patrick Thomas, CEO, Bayer MaterialScience | ||
| Yueksel Karaaslan, Member of the Supervisory Board | ||
| Erica Mann, Member of the Management Board, Head of the Consumer Health Division | ||
| Norbert Bischofberger, Member of the Supervisory Board | ||
| Hartmut Klusik, Member of the Management Board, Director of Human Resources, Technology & Sustainability | ||
| Michael Koenig, Member of the Management Board responsible for Human Resources | ||
| Thomas Win, Vice Chairman of the Supervisory Board | ||
| Jennifer Brendelto, Vice President - Communications of the Consumer Health Division | ||
| Heike Hausfeld, Member of the Supervisory Board | ||
| Peter Hausmann, Member of the Supervisory Board | ||
| Detlef Rennings, Member of the Supervisory Board | ||
| Werner Wenning, Chairman of the Supervisory Board | ||
| Michael Preuss, Gov Communications | ||
| Kemal Malik, Member of Management Board, Chief Medical Officer of Bayer Healthcare and Head of Global Devel. - Bayer Healthcare | ||
| Petra Kronen, Member of the Supervisory Board | ||
| Oliver Zuehlke, Member of the Supervisory Board | ||
| Thomas Elsner, Member of the Supervisory Board | ||
| Alexander Rosar, Head of Investor Relations | ||
| Wolfgang Nickl, CFO, Member of the Management Board | ||
| Paul Achleitner, Member of the Supervisory Board | ||
| Klaus Sturany, Independent Member of the Supervisory Board | ||
| Stefan Oelrich, Member of the Management Board, Head of the Pharmaceuticals Division | ||
| Thomas Ebeling, Member of the Supervisory Board | ||
| Johannes Dietsch, CFO and Member of Management Board | ||
| Gabriel Harnier, Patents Law | ||
| Norbert Winkeljohann, Independent Member of the Supervisory Board | ||
| Clemens Boersig, Member of the Supervisory Board | ||
| Juergen Beunink, Interim Head of Investor Relations | ||
| Otmar Wiestler, Member of the Supervisory Board | ||
| Sabine Schaab, Member of the Supervisory Board | ||
| BerndPeter Bier, Head Taxes | ||
| Wolfgang Plischke, Member of the Supervisory Board |
Bayer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bayer Aktiengesellscha a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0576 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 87.41 B | |||
| Shares Outstanding | 982.42 M | |||
| Shares Owned By Institutions | 47.11 % | |||
| Price To Earning | 321.83 X | |||
| Price To Book | 1.36 X | |||
| Price To Sales | 1.06 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bayer Aktiengesellscha in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bayer Aktiengesellscha's short interest history, or implied volatility extrapolated from Bayer Aktiengesellscha options trading.
Pair Trading with Bayer Aktiengesellscha
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bayer Aktiengesellscha position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bayer Aktiengesellscha will appreciate offsetting losses from the drop in the long position's value.Moving together with Bayer Pink Sheet
| 0.63 | RHHBF | Roche Holding AG | PairCorr |
| 0.61 | RHHBY | Roche Holding Earnings Call Today | PairCorr |
Moving against Bayer Pink Sheet
| 0.77 | NVDA | NVIDIA Financial Report 22nd of May 2024 | PairCorr |
| 0.76 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
| 0.73 | MUSA | Murphy USA Financial Report 7th of May 2024 | PairCorr |
| 0.71 | GDLC | Grayscale Digital Large | PairCorr |
| 0.68 | MBFJF | Mitsubishi UFJ Financial | PairCorr |
The ability to find closely correlated positions to Bayer Aktiengesellscha could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bayer Aktiengesellscha when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bayer Aktiengesellscha - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bayer Aktiengesellschaft to buy it.
The correlation of Bayer Aktiengesellscha is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bayer Aktiengesellscha moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bayer Aktiengesellschaft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bayer Aktiengesellscha can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bayer Aktiengesellschaft. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Bayer Aktiengesellschaft information on this page should be used as a complementary analysis to other Bayer Aktiengesellscha's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for Bayer Pink Sheet analysis
When running Bayer Aktiengesellscha's price analysis, check to measure Bayer Aktiengesellscha's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bayer Aktiengesellscha is operating at the current time. Most of Bayer Aktiengesellscha's value examination focuses on studying past and present price action to predict the probability of Bayer Aktiengesellscha's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bayer Aktiengesellscha's price. Additionally, you may evaluate how the addition of Bayer Aktiengesellscha to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |